




Prevision



Press Release - 4. March 2026

Prevision Medicine adds Multiple Myeloma to their personalized drug-testing portfolio

Prevision Medicine, a Zurich-based techbio start-up and ETH spin-off, announced the expansion of its proprietary personalized drug screening platform, PrevisionOne™, to include Multiple Myeloma (MM).

Currently designed for research-use-only (RUO), the test supports oncologists to rapidly identify the most effective treatment combinations for each individual MM patient. **The test generates patient-specific drug sensitivity profiles, aiding faster, data-driven therapeutic decisions in the treatment of MM patients.** Following the successful launch of its drug screening solutions for Acute Myeloid Leukemia and Glioblastoma, Prevision Medicine continues to expand its platform into additional high-need indications.

MM is an incurable cancer of the bone marrow. Effective management requires timely and carefully sequenced treatment decisions to control symptoms, prevent organ damage, and extend survival.





Prevision

Today, there are numerous approved treatment options for MM across multiple drug classes. These therapies are often combined in doublet, triplet, or quadruplet regimens for both newly diagnosed and relapsed or refractory patients. While this expanding therapeutic landscape has improved outcomes, it has also increased the complexity of treatment selection. **Identifying the most effective combination for an individual patient at a given time is a critical and challenging task.**

Prevision Medicine's MM Drug Screening Test addresses this challenge by systematically evaluating available treatment options on primary cancer and healthy cells to determine the most effective combination for each patient. Using only a small sample of bone marrow, the test provides actionable insights that support personalized, evidence-based treatment decisions within an increasingly complex therapeutic space.

“Despite significant therapeutic advances, treating Multiple Myeloma remains highly complex, requiring careful selection of combination therapies **for each individual patient.**

PrevisionOne's high-throughput drug screening capabilities enable oncologists to navigate this complexity with functional and data-driven therapeutic decisions of MM patients, helping identify the most effective treatment combinations to **improve disease control and patient outcomes.**”

Dr. Philip Zimmermann
CEO Prevision Medicine





The MM RUO test is built on findings from a comprehensive observational clinical study recently published in Nature Cancer conducted in collaboration with the University Hospital Zurich. The study demonstrates that image-based ex vivo drug testing (“pharmacoscopy”) can accurately predict clinical patient responses to both standard-of-care and complex immunotherapy-containing treatment regimens.

Key Features of the MM Drug Screening Test

An extensive drug panel evaluating up to 56 individual approved drugs and drug combinations, encompassing a wide range of Multiple Myeloma (MM) treatments. These include proteasome inhibitors, IMiDs, corticosteroids, and alkylating agents, alongside cutting-edge immunotherapies such as monoclonal antibodies, antibody-drug conjugates, and bispecific T-cell engagers.

Fast results, with an average 72 hours turn-around time from sample reception to test report.

Generated by our Proprietary PrevisionOne™ platform, delivering functional, patient-specific drug response data on how their cells respond to different cancer drugs.

Rooted in Pharmacoscopy: The clinically most validated functional precision medicine method which uses image-based single-cell data to evaluate ex vivo patient drug responses.



About

Prevision Medicine is a Swiss-based techbio company building an evidence-driven platform for functional precision oncology. Its proprietary PrevisionOne™ platform generates high-dimensional drug response data from patient samples, transforming complex biological signals into actionable insights that support personalized treatment strategies across multiple cancer types.

For more information, please visit:

www.previsionmedicine.com

General and Business Inquiries

Valentin Matillon, Chief Business Officer

valentin@previsionmedicine.com

Media Inquiries

info@previsionmedicine.com

